These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 31665468)

  • 21. New Therapeutic Approaches to Large-Vessel Vasculitis.
    Kaymakci MS; Warrington KJ; Kermani TA
    Annu Rev Med; 2024 Jan; 75():427-442. PubMed ID: 37683286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
    Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
    Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool.
    Sebastian A; Kayani A; Prieto-Pena D; Tomelleri A; Whitlock M; Mo J; van der Geest N; Dasgupta B
    RMD Open; 2020 Nov; 6(3):. PubMed ID: 33161376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Large-vessel vasculitis-giant cell and Takayasu arteritis].
    Villiger PM
    Internist (Berl); 2019 Oct; 60(10):1059-1073. PubMed ID: 31471629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review.
    Sakai R; Kondo T; Kurasawa T; Nishi E; Okuyama A; Chino K; Shibata A; Okada Y; Takei H; Nagasawa H; Amano K
    Clin Rheumatol; 2017 Oct; 36(10):2383-2392. PubMed ID: 28733791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis.
    Marvisi C; Ricordi C; Galli E; Muratore F; Boiardi L; Macchioni PL; Pipitone N; Macaluso F; Salvarani C; Brandolino F
    Clin Exp Rheumatol; 2023 Apr; 41(4):975-981. PubMed ID: 37073638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
    Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
    Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis.
    Matsumoto K; Suzuki K; Yoshimoto K; Seki N; Tsujimoto H; Chiba K; Takeuchi T
    Arthritis Res Ther; 2019 Dec; 21(1):304. PubMed ID: 31888748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center.
    Nielsen MK; Nielsen AW; Donskov AO; Hansen IT; Nielsen BD; Mørk C; Hauge EM; Keller KK
    Semin Arthritis Rheum; 2024 Oct; 68():152508. PubMed ID: 38981187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
    Maz M; Chung SA; Abril A; Langford CA; Gorelik M; Guyatt G; Archer AM; Conn DL; Full KA; Grayson PC; Ibarra MF; Imundo LF; Kim S; Merkel PA; Rhee RL; Seo P; Stone JH; Sule S; Sundel RP; Vitobaldi OI; Warner A; Byram K; Dua AB; Husainat N; James KE; Kalot MA; Lin YC; Springer JM; Turgunbaev M; Villa-Forte A; Turner AS; Mustafa RA
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1071-1087. PubMed ID: 34235871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study.
    Samec MJ; Rakholiya J; Langenfeld H; Crowson CS; Abril A; Wang B; Mertz L; Rodriguez-Pla A; Bansal P; Burke M; Jaquith J; Weyand C; Warrington KJ; Koster MJ
    J Rheumatol; 2023 Oct; 50(10):1310-1317. PubMed ID: 37321636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
    Schmitt C; Brockwell L; Giraudon M; Zucchetto M; Christ L; Bannert B; Daikeler T; Villiger PM
    Arthritis Res Ther; 2022 Jun; 24(1):133. PubMed ID: 35659282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab and refractory Takayasu disease: Four case reports and systematic review.
    Decker P; Olivier P; Risse J; Zuily S; Wahl D
    Autoimmun Rev; 2018 Apr; 17(4):353-360. PubMed ID: 29427826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
    Hellmich B; Águeda AF; Monti S; Luqmani R
    Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy.
    Higashida-Konishi M; Akiyama M; Shimada T; Hama S; Oshige T; Izumi K; Oshima H; Okano Y
    Rheumatol Int; 2023 Mar; 43(3):545-549. PubMed ID: 36152056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
    Narváez J; Estrada P; LLop D; Vidal-Montal P; Brugarolas E; Maymó-Paituvi P; Palacios-Olid J; Nolla JM
    Semin Arthritis Rheum; 2023 Apr; 59():152166. PubMed ID: 36645992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases.
    Boiardi L; Galli E; Macchioni P; Muratore F; Klinowski G; Hunder GG; Casali M; Besutti G; Spaggiari L; Versari A; Croci S; Mancuso P; Rossi PG; Marvisi C; Salvarani C
    Semin Arthritis Rheum; 2023 Apr; 59():152173. PubMed ID: 36780709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment failure in giant cell arteritis.
    Unizony SH; Bao M; Han J; Luder Y; Pavlov A; Stone JH
    Ann Rheum Dis; 2021 Nov; 80(11):1467-1474. PubMed ID: 34049857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosis of large vessel involvement in large vessel vasculitis.
    Vautier M; Dupont A; de Boysson H; Comarmond C; Mirault T; Mekinian A; Lambert M; Ferfar Y; Aouba A; Cacoub P; Resche-Rigon M; Saadoun D
    J Autoimmun; 2020 Mar; 108():102419. PubMed ID: 32035747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.